Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Vaccine crawled time : 01:00 save search
Empowering Healthcare: Global Vaccine Management System Market to Reach $441.17 million by 2028
Published: 2023-08-30 (Crawled : 01:00) - prnewswire.com
GLAXF | News | $19.54 -3.77% -14.18% 0
|
Health Technology
|
| O: -1.57%
H: 0.0%
C: 0.0%
AZNCF | News | $135.35 -3.53% -4.19% 0
|
Health Technology
|
| O: 0.56%
H: 0.0%
C: -2.26%
NVS | News | $98.35 1.1% 0.32% 5.9K
|
Health Technology
|
| O: -0.25%
H: 0.47%
C: -1.08%
JNJ | News | $148.53 -0.69% 0.11% 67K
|
Health Technology
|
| O: 0.56%
H: 0.0%
C: 0.0%
GSK | News | $40.86 -0.92% 0.91% 11K
|
Health Technology
|
| O: 0.54%
H: 0.27%
C: -0.59%
SNY | News | $46.61 -2.27% -2.21% 220K
|
Health Technology
|
| O: 0.66%
H: 0.0%
C: 0.0%
AZN | News | $71.2 0.49% 0.46% 300K
|
Health Technology
|
| O: 0.46%
H: 0.17%
C: -0.86%
management vaccine reach global system market
Europe Human Papillomavirus Vaccine Market Report 2022: Sector to Reach $1.59 Billion by 2028 at a 4.9% CAGR
Published: 2023-01-27 (Crawled : 01:00) - prnewswire.com
GLAXF | News | $19.54 -3.77% -14.18% 0
|
Health Technology
|
| O: 1.13%
H: 1.57%
C: 1.57%
GSK | News | $40.86 -0.92% 0.91% 11K
|
Health Technology
|
| O: -0.03%
H: 0.3%
C: -0.08%
SNY | News | $46.61 -2.27% -2.21% 220K
|
Health Technology
|
| O: -1.25%
H: 0.0%
C: 0.0%
europe report vaccine market
Clover Provides Updates on COVID-19 Vaccine Commercial Launch and Strategic Priorities in 2023
Published: 2023-01-16 (Crawled : 01:00) - globenewswire.com
DVAX | $11.285 -1.18% 110K
|
Health Technology
| Email alert
Add to watchlist
covid-19 clover vaccine commercial
Icosavax Reports Positive Durability Data for VLP Vaccine Candidate IVX-121 Against RSV at Six-Month Timepoint
Published: 2022-12-13 (Crawled : 01:00) - biospace.com/
ICVX | $15.31 -0.65% 9.3M
|
|
| O: 2.37%
H: 16.75%
C: 8.25%
ivx-121 candidate vaccine positive
Icosavax Announces Positive Topline Interim Phase 1/1b Results for VLP Vaccine Candidate IVX-121 Against RSV
Published: 2022-06-28 (Crawled : 01:00) - biospace.com/
ICVX | $15.31 -0.65% 9.3M
|
|
| O: 2.12%
H: 0.0%
C: -7.88%
ivx-121 candidate topline vaccine positive phase 1
Clover Doses First Participants in Phase 3 Trial Evaluating SCB-2019 as a Heterologous COVID-19 Booster Following Prior Vaccination with Inactivated, mRNA or Viral Vector Vaccines
Published: 2022-06-14 (Crawled : 01:00) - globenewswire.com
DVAX | $11.285 -1.18% 110K
|
Health Technology
|
| O: -5.45%
H: 3.46%
C: 0.67%
scb-2019 covid-19 clover mrna trial phase 3 vaccine
Philip R. Krause, M.D., Former FDA Deputy Chief for Vaccines, Joins Mesoblast Board
Published: 2022-03-24 (Crawled : 01:00) - globenewswire.com
MESO | $6.22 3.67% 3.38% 520
|
Health Technology
|
| O: 2.4%
H: 4.45%
C: 3.98%
fda vaccine
Blue Water Vaccines Announces Pricing of approximate $20M Initial Public Offering
Published: 2022-02-18 (Crawled : 01:00) - globenewswire.com
BWV | $0.1802 5.44% 530K
|
| Email alert
Add to watchlist
offering blue vaccine
Vaccinex Reports Two Complete Responses in First Three Patients Enrolled in the Phase 1b/2 KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or Metastatic Head and Neck Cancer
Published: 2022-01-26 (Crawled : 01:00) - globenewswire.com
VCNX | $5.005 1K
|
Health Technology
|
| O: 21.57%
H: 3.23%
C: -10.48%
ema phase 1b response pepinemab phase 1 keytruda report pons cancer vaccine enroll phase 2b
HHCGA, CORE, and The City of Lilburn Organizes Vaccine Event for the Lilburn Community
Published: 2022-01-25 (Crawled : 01:00) - prnewswire.com
JNJ | News | $148.53 -0.69% 0.11% 67K
|
Health Technology
|
| O: -0.05%
H: 1.0%
C: 0.5%
vaccine
Australia Therapeutic Goods Administration (TGA) Grants Provisional Registration for Novavax COVID-19 Vaccine
Published: 2022-01-19 (Crawled : 01:00) - prnewswire.com
NVAX | $4.15 -0.96% -0.96% 18K
|
Health Technology
|
| O: 2.59%
H: 3.89%
C: -4.6%
covid-19 covid tga australia vaccine granted grant
Health Canada receives submission from Pfizer-BioNTech to authorize the use of Comirnaty COVID-19 vaccine in children 5 to 11 years of age
Published: 2021-10-18 (Crawled : 01:00) - biospace.com/
BNTX | News | $87.62 -0.53% 29K
|
Health Technology
|
| O: -0.94%
H: 6.44%
C: 6.42%
covid children vaccine submission comirnaty®
Vaxcyte to Present at Guggenheim 2nd Annual Vaccine and Infectious Disease Conference
Published: 2021-09-28 (Crawled : 01:00) - globenewswire.com
PCVX | $60.3 -0.95% -1.05% 3
|
Health Technology
|
| O: 1.24%
H: 1.04%
C: -1.23%
STRO | $3.47 -6.72% -7.2% 1.7K
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: -2.25%
disease infectious disease vaccine conference
Results from Novavax NanoFlu Influenza Vaccine Phase 3 Clinical Trial Published in The Lancet Infectious Diseases
Published: 2021-09-24 (Crawled : 01:00) - prnewswire.com
NVAX | $4.15 -0.96% -0.96% 18K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
disease infectious disease results vaccine influenza phase 3 trial lancet
Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response
Published: 2021-07-01 (Crawled : 01:00) - prnewswire.com
JNJ | News | $148.53 -0.69% 0.11% 67K
|
Health Technology
|
| O: 0.04%
H: 1.98%
C: 1.78%
covid positive vaccine
Ocugen On Track to Submit Emergency Use Authorization Application to U.S. FDA for its COVID-19 Vaccine Candidate, COVAXIN™
Published: 2021-05-27 (Crawled : 01:00) - globenewswire.com
OCGN | News 4 | $1.18 -5.6% -6.84% 97K
|
Health Technology
|
| O: 0.91%
H: 13.32%
C: 12.68%
covid fda vaccine merge authorized application emergency use authorization
New England Journal of Medicine Publishes Phase 2b Clinical Trial Results Demonstrating Efficacy of Novavax COVID-19 Vaccine Against the B.1.351 Variant
Published: 2021-05-05 (Crawled : 01:00) - biospace.com/
NVAX | $4.15 -0.96% -0.96% 18K
|
Health Technology
|
| O: 3.47%
H: 4.31%
C: -8.13%
covid phase 2 results vaccine phase 2b trial trial results
Novavax to Present COVID-19 Vaccine Candidate Data at New York Academy of Science
Published: 2021-02-02 (Crawled : 01:00) - globenewswire.com
NVAX | $4.15 -0.96% -0.96% 18K
|
Health Technology
|
| O: 0.44%
H: 0.86%
C: -1.88%
covid vaccine covid-19
Ocugen Establishes Vaccine Scientific Advisory Board
Published: 2020-12-24 (Crawled : 01:00) - globenewswire.com
OCGN | News 4 | $1.18 -5.6% -6.84% 97K
|
Health Technology
|
| O: -13.85%
H: 0.45%
C: -21.43%
vaccine
Novavax Announces Agreement with Government of New Zealand for 10.7 Million Doses of COVID-19 Vaccine
Published: 2020-12-17 (Crawled : 01:00) - globenewswire.com
NVAX | $4.15 -0.96% -0.96% 18K
|
Health Technology
|
| O: 2.98%
H: 6.57%
C: 5.84%
vaccine covid covid-19
Gainers vs Losers
| 50% | 50% |
Top 10 Gainers
CSSE 4 | $0.299 96.32% 7M
|
Consumer Services
BRFH 4 | $1.99 80.91% 13M
|
Manufacturing
BOF | $1.915 63.68% 620K
|
AMST | $3.13 56.5% 500K
|
Technology Services
ACON | $0.3595 24.83% 3.5M
|
n/a
CDTX | News | $14.57 18.55% 330K
|
Health Technology
ULBI M | $10.12 15.92% 120K
|
Producer Manufacturing
LRHC | $1.79 11.88% 3K
|
n/a
AIXI | $1.34 8.94% 42K
|
n/a
TRU | $74.475 8.44% 100K
|
Technology Services
Your saved searches
Save your searches and get alerts when important news are released.